Antitumor effects of ribavirin in combination with TMZ and IFN-β in malignant glioma cells
| Autor: | Yutaka Suzuki, Koichiro Sumi, Atsuo Yoshino, Shun Yamamuro, Emiko Sano, Hiroyuki Hara, Akiyoshi Ogino, Takuya Ueda, Sodai Yoshimura, Yushi Ochiai, Tomohiro Nakayama, Yoichi Katayama |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cancer Research ribavirin medicine.medical_treatment temozolomide 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Interferon Glioma Medicine Chemotherapy Temozolomide business.industry Ribavirin glioblastoma apoptosis Cancer Articles interferon Cell cycle medicine.disease Molecular medicine 030104 developmental biology Oncology chemistry 030220 oncology & carcinogenesis Cancer research business medicine.drug |
| Zdroj: | Oncology Letters |
| ISSN: | 1792-1074 |
| Popis: | The prognosis of gioblastoma, the standard chemotherapy agent for which is temozolomide (TMZ), remains poor despite recent advances in multimodal treatments. Therefore, it is necessary to identify and develop novel therapeutics for this malignant disease. Ribavirin, an anti-viral agent which is one of the standard agents for treatment of chronic hepatitis C in combination with interferon (IFN), was recently revealed to have an antitumor potential towards various tumor cells, including malignant glioma cells. The aim of the present study was to examine the antitumor effect of ribavirin in combination with TMZ and IFN-β on glioma cells and to evaluate the possibility that such combinations might represent a novel candidate for glioblastoma therapy. The combination of ribavirin with TMZ and IFN-β displayed a significant cell growth inhibitory effect with a ribavirin dose-dependency, including a relatively low concentration of ribavirin, on not only TMZ-sensitive but also TMZ-resistant malignant glioma cells. The antitumor efficacy of such a combination further indicated a synergistic interaction when assessed by the Chou-Talalay method. Furthermore, flow cytometry analysis suggested that apoptosis induction was one of the possible biological processes underlying the synergistic antitumor effect of these triple combination treatments. Therefore, such combinations may be potentially important in the clinical setting for glioblastoma treatment, although further detailed studies, e.g. on the adverse effects, are required. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|